Reacting to crises: The COVID-19 impact on biostatistics/epidemiology.
Contemp Clin Trials
; 102: 106214, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-917234
ABSTRACT
Most crises, though difficult and challenging to address, offer opportunities for change and for development of new perspectives or approaches to deal with traditional strategies. The reaction to and the managing of the COVID-19 pandemic has provided a platform for evaluating how we quantify disease prevalence, incidence, time courses and sequellae as well as how well we plan, design, analyze and interpret health care associated data, including clinical trials and electronic medical records and health claims data. Whether the Covid-19 crisis provides opportunities to advance the fields of biostatistics and epidemiology in select ways remains to be seen. This article describes three areas of crises experienced by the author during a career in the regulation of pharmaceutical products and how they were responded to. Some suggestions for potential future opportunities in reaction to the Covid-19 crises are provided.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Epidemiology
/
Biostatistics
/
Data Collection
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Contemp Clin Trials
Journal subject:
Medicine
/
Therapeutics
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS